MOTS-C

Last Updated: August 2026

MOTS-c is a 16-amino-acid mitochondrial-derived peptide encoded within the mitochondrial 12S rRNA gene, identified in 2015 as the first member of the mitochondrial-derived peptide (MDP) family. Research interest focuses on metabolic regulation, insulin sensitivity, exercise mimicry, and potential longevity applications. MOTS-c is not approved for any medical indication and is sold as a research-use-only compound by third-party laboratories.

What is MOTS-c and how does the mitochondrial-derived mechanism work?

MOTS-c (mitochondrial open reading frame of the 12S rRNA-c) is a 16-amino-acid mitochondrial-derived peptide, identified in 2015 by the Lee lab (Changhan Lee and colleagues) as a regulator of metabolic homeostasis, obesity, and insulin resistance in mice1 source and proposed to regulate metabolic homeostasis through AMPK activation, GLUT4 translocation, and direct mitochondrial-to-nuclear signaling. The peptide is endogenously expressed but with declining serum levels in older adults — preclinical work suggests exogenous supplementation may compensate for age-related decline. Evidence level: Preclinical (rodent metabolism, exercise capacity, insulin sensitivity); no published interventional human data.

What does the research show for MOTS-c?

In preclinical rodent studies, MOTS-c administration improved glucose tolerance, reduced age-related insulin resistance, enhanced exercise capacity, and extended healthspan in some models. Human clinical data is sparse: no interventional trial of administered MOTS-c has been published in any indication as of August 2026. Human evidence is limited to observational work on naturally occurring (endogenous) MOTS-c — for example, circulating MOTS-c levels decline with age — plus community-reported research use. The metabolic and exercise-capacity findings the compound is known for come from rodent studies. the mechanism translates plausibly from rodent to human but efficacy translation has not been clinically established. Evidence level: Preclinical (multiple rodent studies, in vitro mechanism). Human translation: not yet established at Phase 2/3 scale.

How does MOTS-c compare to GLP-1-class weight-loss peptides?

MOTS-c is not a weight-loss peptide in the same category as GLP-1 agonists — it does not produce the appetite suppression or large-magnitude weight loss seen with semaglutide, tirzepatide, or retatrutide. MOTS-c is researched for metabolic health markers (insulin sensitivity, mitochondrial function, exercise tolerance) rather than direct weight reduction. Comparing MOTS-c to GLP-1 compounds on weight loss is a category error.

What are the documented side effects of MOTS-c?

Human safety data for MOTS-c is limited. In community-reported research use, side effects have been described as mild and infrequent, but without controlled human trials this cannot be characterized reliably — typically injection-site reactions and occasional gastrointestinal effects. Preclinical rodent studies have not surfaced significant toxicity signals at researched doses. Long-term safety in humans is unknown. Evidence level: Preclinical safety; no controlled human trials; long-term human safety unestablished.

What is the regulatory status of MOTS-c?

MOTS-c is not approved for any medical indication anywhere in the world as of August 2026. On April 22, 2026 the FDA removed MOTS-c from its Category 2 bulk drug substances list because the nomination had been withdrawn by the nominators — this did not add it to Category 1 or the 503A bulks list.1 source At the July 23–24, 2026 Pharmacy Compounding Advisory Committee meeting, the committee voted 7–5–2 to recommend MOTS-c for the 503A compounding bulks list. That recommendation is advisory only: FDA scientific staff opposed it, and compounding stays unlawful under 503A until the FDA completes formal rulemaking, not expected before 2027.1 source It is sold strictly as a research-use-only compound by third-party laboratories. No clinical trial program for MOTS-c is currently advancing toward an NDA. Buyers should treat MOTS-c as an early-stage research peptide with strong preclinical signals but unestablished human efficacy. Regulatory context in are peptides legal.

Why does MOTS-c vendor verification matter?

MOTS-c synthesis is mature enough that production quality across vendors is generally good, but the small molecular size (16 amino acids) and limited demand mean fewer labs have optimized large-batch production — creating variance in purity and identity confirmation across vendors. Independent HPLC purity testing and mass spectrometry identity confirmation are the meaningful purity signals. Guidance in our how-to-test-peptides hub.

How does Peptigrity verify MOTS-c vendors?

Peptigrity collects independent third-party Certificates of Analysis for MOTS-c from shops' official channels and verifies each for authenticity before publishing. Because shops choose which COAs to publish, results reflect the batches shops have made public rather than every production batch — a selection bias we state openly. A community-funded Testing Grant to purchase and test vials anonymously is in development. The lab test table above this section shows the cross-shop dataset. Tests come from independent labs including Janoshik Analytical, Freedom Diagnostics, and Chromate. Methodology in how we calculate trust scores.

Frequently Asked Questions

Is MOTS-c a weight-loss peptide?

MOTS-c is researched for metabolic health markers — insulin sensitivity, mitochondrial function, exercise capacity — not primarily for weight loss. It is not in the same therapeutic category as GLP-1 receptor agonists. Users seeking direct weight-loss compounds should reference semaglutide, tirzepatide, or retatrutide.

Is MOTS-c legal to purchase?

MOTS-c is legal to purchase as a research chemical for laboratory use in most jurisdictions, but it is not approved for human consumption. Country breakdown in peptide legal status guide.

What does the human evidence show for MOTS-c?

Human evidence for MOTS-c is limited to observational studies of endogenous MOTS-c and community-reported research use. No interventional human trial of administered MOTS-c — Phase 1, 2, or 3 — has been published in any indication as of August 2026; the efficacy data are preclinical. The preclinical signal in rodents is strong but human translation has not been clinically established at scale.

How can I verify a MOTS-c vendor is selling real product?

Independent third-party HPLC certificate of analysis from a lab the vendor does not own or pay. Peptigrity publishes independent MOTS-c test results from independent labs in the table above. COA interpretation in red flags in peptide certificates of analysis.

Does Peptigrity recommend a MOTS-c dose?

No. MOTS-c is not approved for human consumption and Peptigrity is an independent review platform, not a medical authority. Research-use dosing in preclinical studies has varied widely; translation to a human research protocol is medical practice. Anyone considering investigational compound use should consult a licensed physician.

What's the longevity angle on MOTS-c?

The longevity hypothesis for MOTS-c rests on preclinical rodent data showing healthspan extension in some models and the observation that endogenous MOTS-c serum levels decline with age in humans. The hypothesis is mechanistically plausible but unestablished clinically. Treat longevity claims for MOTS-c with the appropriate skepticism — the evidence stage is preclinical, not human RCT.

This section is for educational and informational purposes only and does not constitute medical advice. MOTS-c is not approved by the FDA or any other regulator for human use. Always consult a qualified healthcare provider before using any peptide or research compound. Peptigrity is an independent review platform and does not sell, endorse, or recommend specific products or vendors.